Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210
- PMID: 26206559
- DOI: 10.1158/0008-5472.CAN-15-0405
Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210
Abstract
Myeloid-derived suppressor cells (MDSC) contribute significantly to the malignant characters conferred by hypoxic tumor microenvironments. However, selective biomarkers of MDSC function in this critical setting have not been defined. Here, we report that miR-210 expression is elevated by hypoxia-inducible factor-1α (HIF1α) in MDSC localized to tumors, compared with splenic MDSC from tumor-bearing mice. In tumor MDSC, we determined that HIF1α was bound directly to a transcriptionally active hypoxia-response element in the miR-210 proximal promoter. miR-210 overexpression was sufficient to enhance MDSC-mediated T-cell suppression under normoxic conditions, while targeting hypoxia-induced miR-210 was sufficient to decrease MDSC function against T cells. Mechanistic investigations revealed that miR-210 modulated MDSC function by increasing arginase activity and nitric oxide production, without affecting reactive oxygen species, IL6, or IL10 production or expression of PD-L1. In splenic MDSC, miR-210 regulated Arg1, Cxcl12, and IL16 at the levels of both mRNA and protein, the reversal of which under normoxic conditions decreased T-cell-suppressive effects and IFNγ production. Interestingly, miR-210 overexpression or targeting IL16 or CXCL12 enhanced the immunosuppressive activity of MDSC in vivo, resulting in increased tumor growth. Taken together, these results provide a preclinical rationale to explore miR-210 inhibitory oligonucleotides as adjuvants to boost immunotherapeutic responses in cancer patients.
©2015 American Association for Cancer Research.
Similar articles
-
Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.J Immunol. 2014 Feb 1;192(3):1320-31. doi: 10.4049/jimmunol.1203195. Epub 2013 Dec 30. J Immunol. 2014. PMID: 24379122
-
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.J Exp Med. 2014 May 5;211(5):781-90. doi: 10.1084/jem.20131916. Epub 2014 Apr 28. J Exp Med. 2014. PMID: 24778419 Free PMC article.
-
MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells.J Immunol. 2014 Feb 1;192(3):1034-43. doi: 10.4049/jimmunol.1301309. Epub 2014 Jan 3. J Immunol. 2014. PMID: 24391219
-
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s. doi: 10.1158/1078-0432.CCR-06-2197. Clin Cancer Res. 2007. PMID: 17255300 Review.
-
[Myeloid-derived suppressor cells - the new mechanism of immunosuppression in cancer].Postepy Hig Med Dosw (Online). 2008 Jan 21;62:18-22. Postepy Hig Med Dosw (Online). 2008. PMID: 18219264 Review. Polish.
Cited by
-
Hypoxia-Related Gene-Based Signature Can Evaluate the Tumor Immune Microenvironment and Predict the Prognosis of Colon Adenocarcinoma Patients.Int J Gen Med. 2021 Dec 16;14:9853-9862. doi: 10.2147/IJGM.S343216. eCollection 2021. Int J Gen Med. 2021. PMID: 34938106 Free PMC article.
-
Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma.J Cancer. 2022 May 16;13(8):2631-2643. doi: 10.7150/jca.70725. eCollection 2022. J Cancer. 2022. PMID: 35711827 Free PMC article.
-
A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia.Sci Rep. 2021 Jul 19;11(1):14657. doi: 10.1038/s41598-021-94128-1. Sci Rep. 2021. PMID: 34282207 Free PMC article.
-
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity.Oncoimmunology. 2021 Jul 25;10(1):1950953. doi: 10.1080/2162402X.2021.1950953. eCollection 2021. Oncoimmunology. 2021. PMID: 34367731 Free PMC article.
-
Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.J Exp Clin Cancer Res. 2021 Jan 9;40(1):24. doi: 10.1186/s13046-020-01820-7. J Exp Clin Cancer Res. 2021. PMID: 33422072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous